4-(1-甲基乙基)-1-哌嗪丙醇 | 86585-74-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(1-甲基乙基)-1-哌嗪丙醇
• 英文名称: 3-(4-isopropyl-piperazino)-propan-1-ol
• 英文别名: 3-(4-Isopropylpiperazin-1-yl)propan-1-ol；3-(4-propan-2-ylpiperazin-1-yl)propan-1-ol
• CAS: 86585-74-2
• 化学式: C₁₀H₂₂N₂O
• 分子量: 186.297
• InChiKey: RZUVZJCXTHNTJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(1-甲基乙基)-1-哌嗪丙醇 在 氯化亚砜 、 氯仿 作用下， 生成 1-(3-chloro-propyl)-4-isopropyl-piperazine, dihydrochloride
  参考文献：
  名称：

  �ber unsymmetrisch substituierte Piperazine

  摘要：

  DOI：

  10.1007/bf00899582
• 作为产物：
  描述：

  N,N-二(2-氯乙基)-2-丙胺 、 3-氨基-1-丙醇 在 乙醇 、 potassium carbonate 作用下， 生成 4-(1-甲基乙基)-1-哌嗪丙醇
  参考文献：
  名称：

  �ber unsymmetrisch substituierte Piperazine

  摘要：

  DOI：

  10.1007/bf00899582

文献信息

• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES
  申请人：Arvinas, Inc.

  公开号：US20190151295A1

  公开（公告）日：2019-05-23

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为白细胞介素-1受体相关激酶4（IRAK-4；目标蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合E3泛素连接酶的Von Hppel-Lindau、cereblon配体的双功能化合物，另一端结合目标蛋白的部分，使得目标蛋白靠近泛素连接酶以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。
• [EN] AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON<br/>[FR] COMPOSÉS D'AMINO-PYRIMIDINE EN TANT QU'INHIBITEURS DE TBKL ET OU D'IKK EPSILON
  申请人：MYREXIS INC

  公开号：WO2011046970A1

  公开（公告）日：2011-04-21

  The invention relates to certain amino-pyrimidine compounds which inhibit TBK1 and/or IKK epsilon and which may therefore find application in treating inflammation, cancer, septic shock and/or Primary open Angle Glaucoma (POAG).

  这项发明涉及抑制TBK1和/或IKK epsilon的某些氨基嘧啶化合物，因此可能在治疗炎症、癌症、感染性休克和/或原发性开角青光眼（POAG）中找到应用。
• N-Alkylated 1,4-Dihydropyridines: New Agents to Overcome Multidrug Resistance.
  作者：Koji OHSUMI、Kazuo OHISHI、Yoshihiro MORINAGA、Ryusuke NAKAGAWA、Yasuyo SUGA、Takaaki SEKIYAMA、Yukio AKIYAMA、Takashi TSUJI、Takashi TSURUO

  DOI：10.1248/cpb.43.818

  日期：——

  New N-alkylated 1, 4-dihydropyridine derivatives were synthesized and their ability to overcome multidrug resistance was examined in vincristine-resistant P388 cells (P388/VCR cells). Compounds that possessed an arylalkyl substituent on the dihydropyridine ring nitrogen were more potent than verapamil in potentiating the cytotoxicity of vincristine against P388/VCR cells. However, neither drug effectively enhanced the antitumor activity of vincristine in tumor-bearing mice. Introduction of basic nitrogen-containing substituents on the side chain of 1, 4-dihydropyridines gave improved activity in vitro and in vivo. The piperazine derivative 12c and 12o were more than 10 times as potent as verapamil in vitro. Four compounds selected for in vivo testing showed superior antitumor activity in P388/VCR-bearing mice in combination with vincristine. The structure-activity relationships of the compounds are discussed.

  新合成的N-烷基化1,4-二氢吡啶衍生物，在长春新碱耐药的P388细胞（P388/VCR细胞）中检测了其克服多药耐药的能力。在二氢吡啶环氮上带有芳烷基取代基的化合物，比维拉帕米更能增强长春新碱对P388/VCR细胞的细胞毒性。然而，这两种药物均未有效地增强长春新碱在携带肿瘤的小鼠中的抗肿瘤活性。在1,4-二氢吡啶的侧链上引入含有碱性氮的取代基，在体外和体内均能提高活性。哌嗪衍生物12c和12o在体外比维拉帕米强10倍以上。选出四种化合物进行体内测试，它们与长春新碱联合使用时，在携带P388/VCR的肿瘤小鼠中显示出优越的抗肿瘤活性。讨论了化合物的构效关系。
• PROCESS FOR PREPARING (METH)ACRYLIC ACID
  申请人：Vogel Bernd

  公开号：US20100029979A1

  公开（公告）日：2010-02-04

  The present invention relates to a process for preparing (meth)acrylic acid, characterized in that a cyclic ester is converted to (meth)acrylic acid in the presence of a catalyst. The (meth)acrylic acid prepared can in particular be converted to (meth)acrylates.

  本发明涉及一种制备（甲基）丙烯酸的方法，其特征在于在催化剂的存在下将环状酯转化为（甲基）丙烯酸。制备的（甲基）丙烯酸可以特别地转化为（甲基）丙烯酸酯。
• PROCESS FOR PREPARING TETRAMETHYL GLYCOLIDE
  申请人：Vogel Bernd

  公开号：US20100010276A1

  公开（公告）日：2010-01-14

  The present invention relates to a process for preparing tetramethylglycolide by heating a composition which comprises at least 50% by weight of 2-hydroxy-isobutyric acid and/or tetramethylglycolide to a temperature of at least 100° C.

  本发明涉及一种制备四甲基乙二酰乙酯的方法，包括将含有至少50%重量的2-羟基异丁酸和/或四甲基乙二酰乙酯的组合物加热至至少100℃的温度。